138 related articles for article (PubMed ID: 24725667)
1. Personalized medicine: present and future of breast cancer management.
Sabatier R; Gonçalves A; Bertucci F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
[TBL] [Abstract][Full Text] [Related]
2. Circulating DNA as biomarker in breast cancer.
Schwarzenbach H; Pantel K
Breast Cancer Res; 2015 Oct; 17(1):136. PubMed ID: 26453190
[TBL] [Abstract][Full Text] [Related]
3. Advancements in Biotechnology and Stem Cell Therapies for Breast Cancer Patients.
Dhoundiyal S; Alam MA
Curr Stem Cell Res Ther; 2024; 19(8):1072-1083. PubMed ID: 37815191
[TBL] [Abstract][Full Text] [Related]
4. Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy.
Zänker KS; Borresen-Dale AL; Huber HP
Biomed Hub; 2016; 1(3):1-9. PubMed ID: 31988890
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy.
Norum JH; Andersen K; Sørlie T
Br J Surg; 2014 Jul; 101(8):925-38. PubMed ID: 24849143
[TBL] [Abstract][Full Text] [Related]
7. How many etiological subtypes of breast cancer: two, three, four, or more?
Anderson WF; Rosenberg PS; Prat A; Perou CM; Sherman ME
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25118203
[TBL] [Abstract][Full Text] [Related]
8. Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
Sonnenblick A; Fumagalli D; Sotiriou C; Piccart M
Cancer Treat Rev; 2014 Oct; 40(9):1089-95. PubMed ID: 25151406
[TBL] [Abstract][Full Text] [Related]
9. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Coates AS; Winer EP; Goldhirsch A; Gelber RD; Gnant M; Piccart-Gebhart M; Thürlimann B; Senn HJ;
Ann Oncol; 2015 Aug; 26(8):1533-46. PubMed ID: 25939896
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
Nicolini A; Ferrari P; Duffy MJ
Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells in breast cancer: applications in personalized medicine.
Lee JS; Magbanua MJM; Park JW
Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
[TBL] [Abstract][Full Text] [Related]
12. Personalised cancer medicine.
Jackson SE; Chester JD
Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
[TBL] [Abstract][Full Text] [Related]
13. Towards Agility in Breast Cancer Treatment Principles as Adopted from Agile Software Engineering.
Odeh Y; Al-Balas M
J Multidiscip Healthc; 2024; 17():1315-1341. PubMed ID: 38545433
[TBL] [Abstract][Full Text] [Related]
14. Implications of Agile Values in Software Engineering for Agility in Breast Cancer Treatment: Protocol for a Comparative Study.
Odeh Y; Al-Balas M
JMIR Res Protoc; 2023 Dec; 12():e53124. PubMed ID: 38051558
[TBL] [Abstract][Full Text] [Related]
15. The potential roles of lncRNA TINCR in triple negative breast cancer.
Azman AA; Siok-Fong C; Rajab NF; Md Zin RR; Ahmad Daud NN; Mohamad Hanif EA
Mol Biol Rep; 2023 Sep; 50(9):7909-7917. PubMed ID: 37442895
[TBL] [Abstract][Full Text] [Related]
16. Identification of Prognostic Biomarkers for Breast Cancer Metastasis Using Penalized Additive Hazards Regression Model.
Tapak L; Hamidi O; Amini P; Afshar S; Salimy S; Dinu I
Cancer Inform; 2023; 22():11769351231157942. PubMed ID: 36968522
[TBL] [Abstract][Full Text] [Related]
17. An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study.
Massafra R; Bove S; La Forgia D; Comes MC; Didonna V; Gatta G; Giotta F; Latorre A; Nardone A; Palmiotti G; Quaresmini D; Rinaldi L; Tamborra P; Zito A; Rizzo A; Fanizzi A; Lorusso V
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565344
[TBL] [Abstract][Full Text] [Related]
18. 'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.
Mehmood S; Faheem M; Ismail H; Farhat SM; Ali M; Younis S; Asghar MN
Front Mol Biosci; 2022; 9():783494. PubMed ID: 35495618
[TBL] [Abstract][Full Text] [Related]
19. Illness Perception and Quality of Life in Patients with Breast Cancer.
Ośmiałowska E; Staś J; Chabowski M; Jankowska-Polańska B
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267522
[TBL] [Abstract][Full Text] [Related]
20. DNMT1 facilitates growth of breast cancer by inducing MEG3 hyper-methylation.
Zhu X; Lv L; Wang M; Fan C; Lu X; Jin M; Li S; Wang F
Cancer Cell Int; 2022 Feb; 22(1):56. PubMed ID: 35109842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
